FTSE MIB
26.626,83 +72,50 (+0,27%) Dow Jones
32.560,60 +316,02 (+0,98%) Nasdaq
11.860,11 +184,57 (+1,58%) Nikkei 225
27.466,61 +520,94 (+1,93%) Petrolio
69,08 -0,59 (-0,85%) Bitcoin EUR
26.094,34 +146,03 (+0,56%)
Valneva SE (VLA.PA)
- GlobeNewswire
VALNEVA - Declaration of shares and voting rights - February 28, 2023
VALNEVA Declaration of shares and voting rightsFebruary 28, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: March 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change wa
- GlobeNewswire
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
Saint-Herblain (France), March 2, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001. As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with regulators. On Febru
- GlobeNewswire
Valneva to Present at the Cowen 43rd Annual Healthcare Conference
Saint-Herblain (France), March 1, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Cowen 43rd Annual Healthcare Conference, to take place in-person March 6 - 8, 2023 in Boston, Massachusetts. Key topics to be covered by Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler include the Company’s late-stage va
